Press Releases

Press Releases

March 2, 2017

Venus MedTech Partnership in China and Key Asian Markets

Keystone Heart and Venus MedTech Announce Partnership for Cerebral Embolic Protection with Transcatheter Heart Valve Systems (TAVR) in China and Key Asian Markets...
Read More
February 27, 2017

Keystone Heart Applauds FDA Advisory Panel for Recognition of The Need for Cerebral Protection Following TAVR

CAESAREA, Israel and TAMPA, Fla., Feb. 27, 2017 /PRNewswire/ -- Keystone Heart Ltd., an emerging medical device company focused on developing cerebral embolic protection...
Read More
February 27, 2017

Keystone Heart Applauds FDA Advisory Panel

Panel feedback echoes recently published NeuroARC research guidelines   CAESAREA, Israel, and TAMPA, Florida — February 27, 2017— Keystone Heart...
Read More
November 1, 2016

Delirium Significantly Associated with Brain Lesions in Patients Post-TAVR According to New Data Released at TCT 2016

According to New Data Released at TCT 2016   Delirium Significantly Associated with Brain Lesions in Patients Post-TAVR   CAESAREA,...
Read More
October 3, 2016

American Journal of Cardiology Reports Data Showing New Brain Lesions in 94% of Patients Following TAVR

CAESAREA, Israel and TAMPA, Fla., Oct. 3, 2016 /PRNewswire/ -- Keystone Heart Ltd., an emerging medical device company focused on developing cerebral protection devices for...
Read More
Triguard

The Only CE Marked Cerebral Embolic Protection Device Designed to Cover all Three Major Aortic Vessels.

Cerebral Embolic Protection Device

Stay Updated on the latest Blogs from Keystone Heart.

Skip to content